cmi_logo.png
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 18, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
Colorado State Unive
Colorado State University Global’s Teaching and Learning Programs Impact K-12 Education in Colorado
April 18, 2024 10:42 ET | Colorado State University Global
Aurora, Colo., April 18, 2024 (GLOBE NEWSWIRE) -- Colorado State University Global (CSU Global), the CSU System’s fully online university, ranked by U.S. News & World Report as a top provider of...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
IMG_5056
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 
April 17, 2024 10:15 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
image1 (1).png
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
April 17, 2024 08:00 ET | Evaxion Biotech
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...
ThinkOn Logo - Colour - Slogan- Transparent.png
ThinkOn enters into a distribution agreement with Arrow Electronics to empower partner ecosystem
April 16, 2024 10:00 ET | Think On Inc.
ThinkOn enters into a distribution agreement with Arrow Electronics to elevate partner ecosystem.
Imugene Limited
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
April 15, 2024 16:09 ET | Imugene Limited
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
RNAZ White background cropped.jpg
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024 09:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 11, 2024 11:00 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Tevogen Logo Notified.png
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET | Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.